Leukemia Clinical Trials in Boston

Showing 601-620 of 1,445 trials

A Study of ZN-c3 in Patients With Ovarian Cancer

NCT04516447

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc140 participantsStarted Oct 2020

Aurora, Colorado, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +21 more locations

COMPLETEDPhase 2< 1 mile

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

NCT03148275

This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Locally Advanced Epithelioid HemangioendotheliomaMetastatic Epithelioid HemangioendotheliomaUnresectable Epithelioid Hemangioendothelioma

National Cancer Institute (NCI)44 participantsStarted Jun 2017

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Palo Alto, California, United States +33 more locations

A Study of ZN-c3 in Patients With Ovarian Cancer

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Leukemia Trials in Other Cities

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

MASA Valve Early Feasibility Study

ABC008 in Subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Milademetan in Advanced/Metastatic Solid Tumors

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.

Other Conditions in Boston